Fidelity Discloses 14.97% stake in Ariad

Fidelity Management & Research Company disclosed today in a 13G filing a 14.97% stake in Ariad Pharmaceuticals (ARIA), a company that focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the U.S.States, Europe, and Japan.

According to the filing, the Boston, Massachusetts-based Fidelity, a wholly-owned subsidiary of FMR LLC, is the beneficial owner of 16,352,596 shares or 14.972% of the Common Stock outstanding of Ariad Pharmaceuticals Incorporated.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.